10-K: TransMedics Reports Strong 2025 Growth, Profitability Amid Expansion

TransMedics Group, Inc. reported significant revenue growth and net income for fiscal year 2025, driven by its OCS technology and National OCS Program, despite identifying a material weakness in internal controls.

Summary

• Total revenue for fiscal year 2025 reached $605.5 million, representing a 37.1% year-over-year growth.
• Net income for fiscal year 2025 was $190.3 million, a substantial increase from $35.5 million in 2024, marking sustained profitability after prior losses.
• The accumulated deficit was reduced to $278.0 million as of December 31, 2025.
• The National OCS Program (NOP) continues to be a key growth driver, offering outsourced organ procurement, OCS perfusion management, and transplant logistics services.
• TransMedics' Organ Care System (OCS) is the only FDA-approved, portable, multi-organ, warm perfusion technology platform for heart, lung, and liver transplants.
• Development has been initiated for OCS Kidney and next-generation OCS Heart and Lung systems, with new clinical trials (ENHANCE Heart and DENOVO Lung) underway.
• A material weakness in internal control over financial reporting was identified concerning inventory movement within the manufacturing network.
• In January 2026, the company entered into a new lease agreement for a new corporate headquarters in Somerville, Massachusetts, with operations expected to transition by January 1, 2028.
• Two adjacent parcels of land in Somerville, Massachusetts, were acquired for $15.0 million each in January 2026.
• Three transplant-related fixed-wing aircraft were acquired in 2025 for $42.9 million, expanding the company's aviation logistics fleet.
• A valuation allowance on U.S. federal and state deferred tax assets was released in the fourth quarter of 2025, resulting in a $103.3 million income tax benefit.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, highlighting significant financial growth, sustained profitability, and strategic expansion of its unique OCS technology and NOP. The material weakness in internal controls and ongoing litigation are notable concerns, but the overall trajectory and market positioning are positive.

Positives

• Achieved significant total revenue growth of 37.1% year-over-year, reaching $605.5 million in 2025.
• Reported substantial net income of $190.3 million in 2025, demonstrating sustained profitability after incurring losses prior to 2024.
• The OCS is the only FDA-approved, portable, multi-organ, warm perfusion technology platform, providing a unique competitive advantage.
• The National OCS Program (NOP) offers a comprehensive, turnkey solution that accelerates OCS adoption and increases transplant volumes.
• Expansion of the NOP with owned and operated private aircraft enhances logistics efficiency and control over organ transportation.
• Possesses a substantial body of strong clinical evidence supporting FDA approvals and the clinical benefits of the OCS.
• Maintains strong relationships within the clinical transplant community and expertise in transplant reimbursement and billing.
• Benefits from robust research and development capabilities and a comprehensive intellectual property portfolio.
• The release of a $103.3 million valuation allowance on deferred tax assets in Q4 2025 positively impacted net income and strengthened the balance sheet.
• Maintains a strong cash position of $488.4 million as of December 31, 2025, expected to fund operations for at least 12 months.

Negatives

• Identified a material weakness in internal control over financial reporting related to a deficiency in control over inventory movement within the manufacturing network.
• Depends on a limited number of customers for a significant portion of its revenue, posing a risk if these relationships change.
• Relies on single-source and sole-source suppliers for many OCS components and sterilization services, creating supply chain vulnerability.
• Has limited experience operating aircraft and continues to depend on certain members of the former Summit management team for successful aviation operations.
• Faces an ongoing class action lawsuit alleging misstatements and omissions that artificially inflated the company's stock price.
• An activist short seller published a disparaging report and petitioned the FDA to suspend OCS approval, which could impact reputation and perception of safety/efficacy.
• International reimbursement for OCS products is not widely established and may require additional, potentially expensive and lengthy, clinical studies.
• Expects operating and capital expenditures to continue increasing for future growth initiatives, which could impact profitability if revenue growth does not keep pace.
• The ability to use net operating losses and research and development credit carryforwards may be subject to limitations due to past or future ownership changes.

Risks

• The fluctuation of financial results from quarter to quarter makes results difficult to predict.
• Ability to attract, train, and retain key personnel is crucial for operations and growth.
• Dependence on the success of the Organ Care System (OCS) means business failure if commercialization is unsuccessful.
• Ability to expand access to the OCS through the National OCS Program (NOP) is critical for long-term growth.
• Ability to improve the OCS platform, including developing next-generation products or expanding into new indications, is essential for future success.
• The timing or results of clinical trials for the OCS, including preand post-approval studies, are uncertain.
• Ability to sustain profitability is not guaranteed, as efforts to grow the business may be costlier than expected.
• Need to raise additional funding, which might not be available on favorable terms or at all, potentially diluting shareholders.
• Ability to use net operating losses and research and development credit carryforwards may be subject to future limitations.
• Identified a material weakness in internal control over financial reporting, with potential for additional material weaknesses.
• Ability to scale manufacturing and sterilization capabilities to meet increasing demand is a challenge.
• The rate and degree of market acceptance of the OCS is uncertain, as surgeons and payors may be slow to adopt new technologies.
• Ability to educate patients, surgeons, transplant centers, and payors on the benefits offered by the OCS is vital for adoption.
• Dependence on a limited number of customers for a significant portion of revenue poses a risk of substantial revenue reduction.
• Ability to maintain regulatory approvals or clearances for OCS products in the United States, European Union, and other jurisdictions.
• Ability to adequately respond to FDA or other competent authorities' follow-up inquiries in a timely manner.
• Impact of healthcare policy changes, including legislation or administrative actions affecting the U.S. healthcare system, OPTN, or FDA.
• Performance of third-party suppliers and manufacturers is critical for product supply.
• Reliance on third parties to transport donor organs and medical personnel for NOP, and ability to grow transplant logistics capabilities, including attracting and retaining pilots and acquiring aircraft.
• Ability to maintain Federal Aviation Administration (FAA) or other regulatory licenses or approvals for aircraft transportation services.
• Price increases of the components of products and maintenance, parts, and fuel for aircraft could adversely affect operating results.
• Manufacturing, sales, marketing, and clinical support capabilities and strategy are key competitive factors.
• Attacks against information technology infrastructure could disrupt operations and affect business results.
• Economic, political, and other risks associated with foreign operations could adversely affect international sales.
• Ability to protect, defend, maintain, and enforce intellectual property rights relating to the OCS and avoid allegations of infringement.
• The pricing of the OCS, as well as reimbursement coverage, impacts market acceptance.
• Regulatory developments in the United States, European Union, and other jurisdictions could affect product commercialization.
• The impact of a shutdown of the U.S. government on operations.
• The extent and success of competing products or procedures that are or may become available.
• Ability to service 1.50% convertible senior notes due 2028.
• Existing and any future indebtedness, including ability to comply with affirmative and negative covenants under credit agreements.
• The impact of any product recalls or improper use of products on reputation and financial results.
• International expansion plans and the costs related thereto.
• Estimates regarding revenue, expenses, and needs for additional financing may prove inaccurate.
• Failure to maintain an ethical and inclusive corporate culture, or damage to reputation, could have a material adverse effect.
• Limited experience operating aircraft and potential failure to achieve anticipated benefits of aircraft operations.
• Operation of aircraft is subject to various risks, and failure to maintain an acceptable safety record may impact customer retention.
• Significant reliance on aircraft manufactured by a single company and spare parts poses risks to business and prospects.
• The availability of pilots to the private aviation industries is limited and may negatively affect operations and financial condition.
• Exposure to operational disruptions due to maintenance and third-party services.
• Significant increases in aviation fuel costs could have a material adverse effect.
• Insurance may become too difficult or expensive to obtain, impacting financial position.
• Aircraft operations are often affected by factors beyond control, such as air traffic congestion, security measures, and regulatory changes.
• Aircraft maintenance costs will increase as the fleet ages.
• Risks associated with climate change, including increased impacts of severe weather events on operations and infrastructure.
• Failure to realize the anticipated benefits of completed or future acquisitions, joint ventures, and strategic investments.
• Failure to manage growth effectively could harm the business.
• Disruptions to business as a result of the relocation of headquarters and general expansion of operations.
• Use of artificial intelligence (AI) and other emerging technologies could adversely impact business and financial results.
• If the company infringes or is alleged to infringe the intellectual property rights of third parties, its business or competitive position could be adversely affected.
• Inability to establish, maintain, or adequately protect intellectual property rights relating to the OCS could harm commercial value and competitive position.
• Inability to obtain patent term extension under the Hatch-Waxman Act could materially harm the business.
• Inability to enforce intellectual property rights throughout the world.
• Inability to protect the confidentiality of trade secrets could harm the value of the OCS and competitive position.
• Subject to claims of misappropriating third-party intellectual property, including trade secrets or know-how.
• Subject to continuing regulation by regulatory authorities and entities, and failure to comply could harm the business.
• Products have been and may in the future be subject to product recalls.
• Failure to maintain necessary FDA approvals for the OCS, or obtain necessary FDA approval for future uses, would prevent commercial sales.
• Failure to maintain the CE mark in the European Union, Northern Ireland, and the UKCA mark in Great Britain would limit market access.
• Failure to obtain and maintain regulatory approval in foreign jurisdictions will limit market opportunities.
• Inadequate reimbursement or funding from governments or third-party payors for OCS purchases and procedures would materially impact revenue and profitability.
• Modifications to products may require new PMAs or PMA supplements, or variations to existing CE marking, potentially causing marketing delays or recalls.
• Failure to comply with the FDA's QSMR or clinical trial requirements could lead to enforcement actions.
• Product liability suits or regulatory delays due to defects in the OCS could be expensive and time-consuming.
• Cyberattacks on medical devices could lead to reputational harm, regulatory investigations, or claims.
• Third parties may attempt to produce counterfeit versions of products, harming sales and reputation.
• Improper marketing or promotion, or misuse/off-label use of the OCS, may harm reputation, lead to liability suits, or regulatory sanctions.
• Legislative or regulatory reforms may make it more difficult and costly to obtain approvals or market products.
• Subject to federal, state, and foreign fraud and abuse laws, health information privacy and security laws, and transparency laws.
• Failure to comply with anti-bribery, anti-corruption, and anti-money laundering laws could result in penalties.
• U.S. federal government shutdowns could adversely affect the business.
• The market price of common stock has been and may continue to be volatile, potentially leading to securities class action litigation.
• Adverse or misleading opinions from securities or industry analysts could cause stock price and trading volume to decline.
• Anti-takeover provisions and Massachusetts law may frustrate attempts to remove or replace the board or effect a change of control.
• Exclusive forum provision in restated articles of organization could discourage lawsuits against the company and its directors/officers.
• Changes in accounting standards and subjective assumptions, estimates, and judgments by management could significantly affect financial condition and results of operations.

Future Outlook

The company expects operating and capital expenditures to increase in the foreseeable future as it focuses on growing commercial sales in the U.S. and select non-U.S. markets, expanding its commercial team and NOP, scaling manufacturing and sterilization operations, and continuing research, development, and clinical trial efforts. This includes expanding R&D and manufacturing capabilities in Italy, seeking regulatory approval for next-generation OCS products and new indications, establishing a new long-term global headquarters, and increasing control of air and ground transport for the NOP. Revenue is anticipated to increase over the long term due to continued NOP growth in the U.S. and potential growth from non-U.S. sales if national healthcare systems begin to reimburse for OCS use. Gross margins are expected to moderately increase over the long term due to economies of scale and improved manufacturing efficiency. The income tax rate is expected to increase in the future following the release of the valuation allowance.

Management Comments

• We believe the use of the OCS combined with the NOP has the potential to significantly increase the number of organ transplants and improve post-transplant outcomes.
• We believe the OCS and the NOP drive significant benefits to all stakeholders in the field of organ transplantation.
• We are committed to our goal of transforming organ transplantation with our OCS platform by establishing the OCS as the standard of care for solid organ transplantation and thereby increasing the utilization of donor organs and improving clinical outcomes.
• We believe that our existing cash will enable us to fund our operating expenses, capital expenditure requirements, and debt service payments for at least 12 months following the filing of our annual report on Form 10-K.

Industry Context

StockSavvy.ai notes that TransMedics operates in the highly specialized and regulated medical technology sector, specifically organ transplantation. Its OCS technology and NOP directly address the limitations of traditional cold storage, positioning it as a leader in the emerging warm perfusion preservation market. Competitors like OrganOx (acquired by Terumo) and XVIVO Perfusion AB offer single-organ warm perfusion systems, while Paragonix Technologies (acquired by Getinge) focuses on cold preservation devices. TransMedics' multi-organ platform and integrated logistics (NOP) provide a distinct competitive advantage by offering an end-to-end solution, potentially increasing market penetration and transplant volumes beyond what single-organ or cold storage solutions can achieve. The ongoing modernization of the OPTN by HRSA also presents both opportunities and uncertainties for the company's NOP.

Comparison to Industry Standards

• TransMedics' OCS is the only FDA-approved, portable, multi-organ, warm perfusion technology platform, differentiating it from competitors like OrganOx (acquired by Terumo Corporation in October 2025) and XVIVO Perfusion AB, which offer single-organ warm perfusion systems for liver and lung, respectively.
• The company's NOP, with its owned and operated private aircraft fleet, provides a comprehensive, integrated logistics solution for organ procurement and delivery, a capability not explicitly matched by other warm perfusion competitors.
• The clinical evidence supporting OCS, including published results from large trials for lung, heart, and liver, aims to demonstrate superiority over static cold storage, a long-standing industry standard. New trials (ENHANCE Heart, DENOVO Lung) are specifically designed to evaluate superiority claims.
• While cold preservation devices from companies like Paragonix Technologies (acquired by Getinge in September 2024) exist, TransMedics' warm perfusion approach represents a 'paradigm shift' in organ preservation, addressing limitations of ischemia, optimization, and viability assessment inherent in cold storage.

Management Changes

Corporate Governance

Legal Proceedings

• A class action lawsuit, Jewik v. TransMedics Group, Inc., et al. (Case No. 1:25-cv-10385), was filed on February 14, 2025, alleging claims under Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5, seeking unspecified damages for investors who purchased shares between February 28, 2023, and January 10, 2025.
• Another similar class action lawsuit, Collins v. TransMedics Group, Inc., et al. (Case No. 1:25-cv-10778), was filed on April 2, 2025.
• The Jewik and Collins actions were consolidated on May 22, 2025, and Lead Plaintiffs were appointed.
• A consolidated amended complaint was filed on August 8, 2025, alleging purported misstatements and omissions in the 2022 Annual Report, earnings calls, and other public statements that artificially inflated the stock price.
• Defendants filed a motion to dismiss on October 7, 2025, with Lead Plaintiffs responding on November 21, 2025, and defendants filing a reply on December 22, 2025; the court's ruling is pending.
• An activist short seller submitted a petition to the FDA requesting the suspension of PMA approval for the OCS, particularly the OCS Liver, due to alleged off-label use, which could impact the perception of product safety and efficacy.

Related Party Transactions

• Dr. Amira Hassanein, sister of Dr. Waleed H. Hassanein (President, Chief Executive Officer, and Director), is employed as the Product Director for the OCS Lung program.
• Dr. Amira Hassanein received total compensation of $0.8 million in 2025, $0.5 million in 2024, and $0.4 million in 2023 for her services.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue and net income growth, but potential negative impact from stock price volatility, ongoing litigation, and the identified material weakness in internal controls. Future equity offerings could lead to dilution.
• Employees: Positive impact from competitive compensation and benefits, career development plans, and a focus on an inclusive work environment. Expected growth may lead to increased hiring.
• Customers (Transplant Centers/Hospitals): Benefit from OCS technology improving transplant outcomes and increasing organ utilization, and the NOP providing efficient procurement and logistics. Potential challenges with reimbursement outside the U.S. could affect adoption.
• Patients: Increased access to life-saving transplants and potentially quicker recovery due to OCS technology.
• Suppliers: Continued demand for components and materials, but reliance on single/sole-source suppliers creates potential supply chain risks.
• Creditors: Improved financial health and profitability enhance the company's ability to service its debt obligations, including the CIBC Credit Agreement and Convertible Senior Notes.

Next Steps

• Continue to grow the adoption of the OCS at existing transplant center customers and expand the number of centers utilizing OCS and NOP.
• Grow the National OCS Program (NOP) by leveraging clinical, logistical, and transportation capabilities.
• Develop the next generation and Gen-3 OCS technology platforms, including expansion into additional organs like OCS Kidney, to improve user experience and facilitate the NOP.
• Expand internationally in key European countries, including adding resources for commercial expansion and market access, and constructing R&D and manufacturing facilities in Italy.
• Initiate and conduct new clinical trials (ENHANCE Heart and DENOVO Lung) to generate clinical evidence demonstrating superiority of OCS to static cold storage methods and enable expanded indications.
• Transition certain operations to the new corporate headquarters in Somerville, Massachusetts, on or before January 1, 2028.
• Opportunistically evaluate acquisitions of additional fixed-wing aircraft to enhance logistics capabilities and support international expansion.
• Implement a remediation plan to address the identified material weakness in internal control over financial reporting, focusing on system-based controls and strengthening review procedures.
• Seek long-term reimbursement for OCS products outside of the United States, which may require undertaking additional clinical studies.

Key Dates

Recommendation

TransMedics demonstrates robust financial performance with significant revenue growth and a strong return to profitability in 2025, driven by its innovative OCS technology and expanding National OCS Program. The company holds a unique market position as the only FDA-approved portable, multi-organ warm perfusion platform, addressing a critical unmet need in organ transplantation. While the identified material weakness in internal controls and ongoing litigation warrant close monitoring, the company's strategic initiatives, including next-generation product development, international expansion, and a solid cash position, suggest continued growth potential. The release of the deferred tax asset valuation allowance further strengthens the balance sheet. For a seasoned investor, the growth trajectory and market leadership outweigh the current operational and legal challenges, making it an attractive long-term investment.

Keywords

TransMedics, OCS, Organ Care System, organ transplant, medical technology, National OCS Program, NOP, warm perfusion, FDA approved, heart transplant, lung transplant, liver transplant, OCS Kidney, biotechnology, healthcare, medical device, SEC filing, 10-K, financial results, profitability, revenue growth, internal controls, aviation logistics, intellectual property, clinical trials, reimbursement, corporate governance, risk management